News ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer ORYX to Present Positive Clinical Data for Oncolytic Virus ParvOryx in Combination with Immune Modulators at CIMT Annual Meeting 2018 Positive data from Phase I/IIa clinical trial in glioblastoma with oncolytic virus ParvOryx published in peer-reviewed journal, Molecular Therapy ORYX to present positive clinical data with oncolytic virus ParvOryx in combination with immune activators at the Third CRI-CIMT-EATI-AACR Conference ORYX reports positive clinical evidence with oncolytic virus ParvOryx in combination with immuno-oncology drugs partnering360/Informa Pharma Intelligence: Interview with ORYX CEO on research partnerships and cancer vaccine studies ORYX Enrols First Patients in a Dose-Escalating Phase I/IIa Pilot Study with Oncolytic Virus ParvOryx to Treat Metastatic Pancreatic Cancer BioCentury: Infectious enthusiasm - How oncolytic viruses are coming of age in cancer immunotherapy combinations